Amoéba S.A. (EPA:ALMIB)

Market Cap	71.64M
Revenue (ttm)	682.46K
Net Income (ttm)	-7.36M
Shares Out	68.89M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,812
Average Volume	250,721
Open	1.048
Previous Close	1.040
Day's Range	0.993 - 1.048
52-Week Range	0.748 - 1.444
Beta	-0.06
RSI	62.63
Earnings Date	Dec 30, 2025

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is based in Chassieu, France.

• Industry: Agricultural Inputs
• Sector: Materials
• Founded: 2010
• Employees: 20
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALMIB

Financial Performance

In 2024, Amoéba's revenue was 601,600, a decrease of -9.44% compared to the previous year's 664,310. Losses were -6.59 million, -53.90% less than in 2023.